REDWOOD CITY, Calif.--(BUSINESS WIRE)--OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with advanced, refractory solid tumors.

A new cancer drug that got its start in San Antonio is showing promising results.

(www.pathcentral.net), the first and only company focused exclusively on the success of the community pathologist, today announced the appointment of genomic pathologist and researcher Shelly Gunn, M.D., Ph.D. to the post of Associate Medical Director, Clinical Genomics.

PathCentral Appoints Shelly Gunn, M.D., Ph.D. as Associate Medical Director, Clinical Genomics

SAN ANTONIO -- A San Antonio cancer doctor is launching an ambitious new project. It’s a unique tumor bank that will help unravel the genetic puzzle of a killer disease. Lori Vanta of San Antonio has been fighting colorectal cancer since 2008. At age 41, she’s already undergone treatment with surgery, radiation and chemotherapy.

FDA report: Cancer drugs in short supply

SA Oncologist reassures patients after word of counterfeit cancer drugs

BROTHERLY LOVE: Valentine's visit lifts sister's spirits